Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.
IPO Year: 2022
Exchange: AMEX
Website: ampiopharma.com
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is
ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with
ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p
MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1November 1, 2023 8:45Virtual Lobby opens.Register for the Conference. If you already
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1November 1, 2023 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to t
ENGLEWOOD, Colo., Oct. 5, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has selected Ascendia Pharmaceuticals, Inc. ("Ascendia") to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain. OA-201 consists of a natural metabolite, formulated as an injectable small molecule product which has demonstrated an active reduction in pain and cartilage degradation in relevant pre-clinical studies.
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2October 5, 2023 9:00 Virtual Lobby opens. Register for the Conference. If you already registered, go back to
MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1October 4, 2023 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go
ENGLEWOOD, Colo., Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, October 5, 2023 at 3:25 pm ET. For investors who are interested in participating, please use the link below to register and receive any conference updates: https://goto.webcasts.com/starthere.jsp?ei=1603287&tp_key=5580ab2cb9&
ENGLEWOOD, Colo., Aug. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company's common stock. The reverse stock split will become effective at 4:01pm ET on September 11, 2023. The Company's common stock is expected to begin trading on a split-adjusted basis on the NYSE American under the same symbol AMPE when the market opens on September 12, 2023 with the new CUSIP number 03209T307. The reverse stock split was approved by the Company's stockholders a
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
3 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
Roth Capital resumed coverage of Ampio Pharmaceuticals with a rating of Buy and set a new price target of $4.00
ENGLEWOOD, Colo., May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form.
ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced that the Company will be hosting a conference call on April 28, 2022 at 8am EDT regarding the update from the Food and Drug Administration with respect to its AP-013 study. Conference Call Details Date/Time: April 28, 2022 at 8am EDT Title: Investor Update Call - FDA Response Letter AP-01
ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST. Conference Call Details Date/Time: March 29, 2022, at 4:30 pm EST Conferencing Link: https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BBAccess Code: 66744 Canada dial-in number (Toll Free): 1 833 950 0062 Canad
ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the modified Intent-to-Treat (mITT) population in the Company's AP-013 study, a Phase 3 clinical trial of the company's lead candidate, Ampion™, in patients suffering from severe osteoarthritis of the knee (OAK). The AP-013 study was designed to confirm the efficacy observed in the first pivotal trial, AP-003-A, and was powered to dete
ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, announced that the Company will be hosting a webinar and conference call today at 4:30pm EST to provide an update on clinical and regulatory progress in osteoarthritis of the knee. Webinar Details Date/Time: March 2, 2022, at 4:30 pm EST Webinar Link: https://event.on24.com/wcc/r/3574331/964B6C5B80DB9EFD05CA55D0977BD0D5 Canada dial-in number (Toll Free): 1 833 950 0062
ENGLEWOOD, Colo., Nov. 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business update call with its chairman and CEO, Mike Martino, at 4:30 p.m. EST on Wednesday, Dec. 1, 2021. Investors and analysts can access via the information provided below: Webcast Link: https://event.on24.com/wcc/r/3543501/784479B739F2EB467C477016E7FAD06A Conference Call (listen only) Canada dial-in number (Toll Free)
ENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call with its CEO and Chairman, Michael Martino, who will provide a corporate and business on Wednesday, December 1, 2021, at 4:30 pm EDT/ 2:30 pm MT. Conference Call & Webcast Wednesday, December 1, 2021, 4:30 pm EDT / 2:30 pm MT Webcast Link (listen only): https://event.on24.com/wcc/r/3543501/784479B739F2EB467C477016E7FAD
ENGLEWOOD, Colo., Nov. 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today reported results for the three- and nine-month periods ended September 30, 2021 and provided a corporate overview and business update. Ms. Holli Cherevka, President and Chief Operating Officer, commented, "This quarter marked an exciting period of growth for drug development in the Ampion platform therapy, both in clinical and preclinical development. We have
ENGLEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT. Conference Call & Webcast:Wednesday, November 10, 2021, 4:30 pm EDT / 2:30 pm MTWebcast Link: https://event.on24.com/wcc/r/3499388/60A0DA16A47D6B146B1AA111CA7
15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
EFFECT - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
POS AM - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
RW - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
SC 13G - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq. to the Company's Board of Directors. The appointment of Ms. Jobes expands the Company's Board of Directors from seven members to eight. "We welcome Elizabeth as an addition to our Board of Directors as we enter into a pivotal period at Ampio," said Mike Martino, Chairman and CEO of Ampio. "Throughout her impress